With health care costs rising and obesity-related conditions impacting workplace productivity, employers are increasingly ...

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

Tirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...

Tirzepatide — a drug that acts both as a GLP-1 agonist and a GIP agonist — is the active ingredient in an even more powerful ...

While the outcomes to weight loss drugs can be positive, Consumer Reports (CR) warns there are important considerations—especially for older adults—before starting these treatments.

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

We recently published an article titled Jim Cramer Discusses These 11 Stocks & President Trump’s Tariffs. In this article, we ...

Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.

It’s hard to turn on the TV these days without seeing ads for drugs like Ozempic, Wegovy, Zepbound or Mounjaro. These ...

Eating Patterns in America” report highlighted the growing year-over-year trend toward at-home dining, with 86% of eating ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.